The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them

Abstract

As of today, only two antiangiogenic monoclonal antibodies plus epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) combinations are FDA and EMA-approved and are recommended by American Society of Clinical Oncology, European Society for Medical Oncology, and National Comprehensive Cancer Network for the first-line treatment of EGFR+ advanced non-small cell lung cancer patients: erlotinib plus bevacizumab and erlotinib plus ramucirumab. However, all treated patients eventually become unresponsive to such drugs, due to several different acquired resistance mechanisms, mainly represented by T790M substitutions and MET amplifications. While osimertinib treatment in T790M+ patients still represents the only approved treatment, MET-TKIs will likely change this status quo in the near future. In fact, existing clinical data strongly support a role for MET-TKI-based combinations in EGFR+ MET-amplified patients, possibly revolutionizing our current treatment algorithm. Chemotherapy plus immunotherapy plus antiangiogenic therapy combinations could also represent another useful addition.

Keywords

NSCLC / EGFR / T790M / MET / bevacizumab / ramucirumab / TKI / resistance mechanisms

References

[1] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] Cheng TY,Baade PD,Nwogu C.The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics.J Thorac Oncol2016;11:1653-71 PMCID:PMC5512876

[3] Fois SS,Zinellu A,Cossu A.Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer.Int J Mol Sci2021;22:612 PMCID:PMC7827915

[4] Casanova ML,Casanova B.A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis.Cancer Res2002;62:3402-7

[5] Lichtenberger BM,Niederleithner H,Petzelbauer P.Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development.Cell2010;140:268-79

[6] Reinmuth N,Xu EC.Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients.Lung Cancer2008;62:193-201

[7] Planchard D,Kerr K.Advanced non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol2018;29:iv192-iv237

[8] National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology non-small cell lung cancer. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf [Last accessed on 13 Oct 2022].

[9] Hanna NH,Temin S.Therapy for stage iv non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update.J Clin Oncol2021;39:1040-91

[10] Rocco D,Gravara LD.Advanced non-small cell lung cancer with activating epidermal growth factor receptor mutation: first line treatment and beyond.Rev Recent Clin Trials2019;14:120-8

[11] Rosell R,Felip E.Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.Lancet Respir Med2017;5:435-44

[12] Seto T,Nishio M.Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.Lancet Oncol2014;15:1236-44

[13] Yamamoto N,Nishio M.Erlotinib plus bevacizumab vs. erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: survival follow-up results of the randomized JO25567 study.Lung Cancer2021;151:20-4

[14] Saito H,Furuya N.Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.Lancet Oncol2019;20:625-35

[15] Kawashima Y,Saito H.Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.Lancet Respir Med2022;10:72-82

[16] Gridelli C,Ciardiello F.BEVERLY: rationale and design of a randomized open-label phase III trial comparing bevacizumab plus erlotinib versus erlotinib alone as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small-cell lung cancer.Clin Lung Cancer2016;17:461-5

[17] Piccirillo MC,Garassino MC.Bevacizumab + erlotinib vs. erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: final analysis of the multicenter, randomized, phase 3 BEVERLY trial.Ann Oncol2021;32:S949-S1039

[18] Zhou Q,Cheng Y.Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study.Cancer Cell2021;39:1279-1291.e3

[19] Nakagawa K,Seto T.Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2019;20:1655-69

[20] Ponce Aix S,Garon EB.RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.Cancer Treat Res Commun2021;27:100378

[21] Nishio M,Reck M.RELAY Study InvestigatorsRamucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.Cancer Sci2020;111:4510-25 PMCID:PMC7734014

[22] Christopoulos P,Roeper J.Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing.Lung Cancer2020;148:105-12

[23] Nishio M,Reck M.1209P RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): association between TP53 status and clinical outcome.Ann Oncol2021;32:S962-3

[24] Nakagawa K,Garon EB.RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non-small cell lung cancer.Clin Cancer Res2021;27:5258-71

[25] Soria JC,Vansteenkiste J.FLAURA InvestigatorsOsimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.N Engl J Med2018;378:113-25

[26] Haratake N,Shimokawa M.Phase III clinical trial for the combination of erlotinib plus ramucirumab compared with osimertinib in previously untreated advanced or recurrent non-small cell lung cancer positive for the L858R mutation of EGFR: REVOL858R (WJOG14420L).Clin Lung Cancer2022;23:e257-63

[27] Zhao Y,Cai X.Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.BMJ2019;367:l5460 PMCID:PMC6778694

[28] Fiala O,Finek J,Bortlicek Z.Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC.Neoplasma2013;60:425-31

[29] Rocco D,Gridelli C.The new immunotherapy combinations in the treatment of advanced non-small cell lung cancer: reality and perspectives.Curr Clin Pharmacol2020;15:11-9 PMCID:PMC7497556

[30] Cortot AB.Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas.Eur Respir Rev2014;23:356-66

[31] Zhong WZ,Wu YL.The resistance mechanisms and treatment strategies for.EGFR8:71358-70 PMCID:PMC5642641

[32] Morgillo F,Fasano M.Mechanisms of resistance to EGFR-targeted drugs: lung cancer.ESMO Open2016;1:e000060 PMCID:PMC5070275

[33] Coleman N,Zhang J,Hong D.Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer.ESMO Open2021;6:100319 PMCID:PMC8637467

[34] Zhang Y,Zhang X.Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC.BMC Med2021;19:245 PMCID:PMC8525046

[35] Zeng L,Jiang W.Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.Lung Cancer2020;141:82-8

[36] Mok TS,Ahn M-J.AURA3 InvestigatorsOsimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer.N Engl J Med2017;376:629-40 PMCID:PMC6762027

[37] Papadimitrakopoulou VA,Han JY.Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.Ann Oncol2020;31:1536-44

[38] Leonetti A,Minari R,Giovannetti E.Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.Br J Cancer2019;121:725-37 PMCID:PMC6889286

[39] Akamatsu H,Hayashi H.Efficacy of osimertinib plus bevacizumab vs. osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer previously treated with epidermal growth factor receptor-tyrosine kinase inhibitor: west Japan oncology group 8715L phase 2 randomized clinical trial.JAMA Oncol2021;7:386-94 PMCID:PMC7791398

[40] Kenmotsu H,Mori K.Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations: WJOG9717L study.J Thorac Oncol2022;17:1098-108

[41] Wang Q,Wang K.MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.J Hematol Oncol2019;12:63 PMCID:PMC6588884

[42] Yang JJ,Shu YQ.A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.Invest New Drugs2021;39:477-87

[43] Sequist LV,Ahn M.Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.Lancet Oncol2020;21:373-86

[44] U. S. National Library of Medicine (NIH). A study comparing savolitinib plus osimertinib vs. savolitinib plus placebo in patients with EGFRm+ and MET amplified advanced NSCLC (CoC). Available from: https://www.clinicaltrials.gov/ct2/show/NCT04606771?term=Savolitinib&cond=NSCLC&draw=3&rank=4 [Last accessed on 13 Oct 2022]

[45] Wu Y,Zhou J.Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.Lancet Respir Med2020;8:1132-43

[46] Park K,Kim D.Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: long-term outcomes of the INSIGHT study.Ann Oncol2019;30:ix159

[47] U. S. National Library of Medicine (NIH). A study of tepotinib plus osimertinib in osimertinib relapsed MET amplified NSCLC (INSIGHT 2). Available from: https://www.clinicaltrials.gov/ct2/show/NCT03940703?term=tepotinib&cond=Nsclc&draw=2&rank=2 [Last accessed on 13 Oct 2022]

[48] Wu YL,Kim DW.Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer.J Clin Oncol2018;36:3101-9

[49] Wu Y,Kim D.Phase 1b/2 study of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated non-small cell lung cancer who received prior therapy: final overall survival and safety.JCO2021;39:9048-9048

[50] U. S. National Library of Medicine (NIH). Study evaluating efficacy and safety of capmatinib in combination with osimertinib in adult subjects with non-small cell lung cancers as second line therapy (GEOMETRY-E). Available from: https://www.clinicaltrials.gov/ct2/show/NCT04816214?term=Capmatinib&cond=NSCLC&draw=2&rank=17 [Last accessed on 13 Oct 2022]

[51] Tanaka I,Miyazawa A.Potential benefits of bevacizumab combined with platinum-based chemotherapy in advanced non-small-cell lung cancer patients with EGFR mutation.Clin Lung Cancer2020;21:273-280.e4

[52] Nogami N,Socinski MA.IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain.J Thorac Oncol2022;17:309-23